Yahoo
HKSE - Delayed Quote HKD

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK)

13.050 -0.130 (-0.99%)
At close: November 6 at 4:08:50 PM GMT+8
View in AlphaSpace Currency in CNY All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Total Revenue
78,126,140.310
77,656,109.939
74,992,820.474
75,515,403.995
70,788,155.068
Cost of Revenue
66,231,662.944
65,045,061.404
62,472,768.682
61,328,109.615
57,510,951.746
Gross Profit
11,894,477.366
12,611,048.535
12,520,051.792
14,187,294.380
13,277,203.323
Operating Expense
9,199,129.096
9,071,680.866
8,744,645.409
9,314,799.447
8,730,402.652
Operating Income
2,695,348.270
3,539,367.670
3,775,406.383
4,872,494.933
4,546,800.671
Net Non Operating Interest Income Expense
-351,701.009
-285,109.240
-35,078.810
16,241.755
173,573.207
Pretax Income
2,689,126.183
3,689,925.942
3,607,579.872
5,110,498.030
5,043,244.071
Tax Provision
461,136.240
629,215.626
606,848.528
851,170.069
789,873.737
Net Income Common Stockholders
2,164,606.831
2,983,113.595
2,835,496.164
4,055,678.691
3,966,522.219
Basic EPS
1.33
1.83
1.74
2.50
2.44
Diluted EPS
1.33
1.83
1.74
2.50
2.44
Basic Average Shares
1,625,565.789
--
1,625,857.892
1,625,522.522
1,625,623.860
Diluted Average Shares
1,625,565.789
--
1,625,857.892
1,625,522.522
1,625,623.860
Total Operating Income as Reported
2,680,297.209
3,628,799.655
3,596,393.913
5,120,896.681
5,074,399.609
Rent Expense Supplemental
39,764.564
38,012.075
35,549.568
31,312.599
43,374.049
Total Expenses
75,430,792.040
74,116,742.270
71,217,414.091
70,642,909.062
66,241,354.397
Net Income from Continuing & Discontinued Operation
2,164,606.831
2,983,113.595
2,835,496.164
4,055,678.691
3,966,522.219
Normalized Income
2,275,387.842
--
--
--
--
Interest Income
101,158.662
141,887.112
404,308.071
486,336.349
626,789.186
Interest Expense
414,497.402
401,507.404
418,151.318
446,191.733
434,408.024
Net Interest Income
-351,701.009
-285,109.240
-35,078.810
16,241.755
173,573.207
EBIT
3,103,623.585
4,091,433.347
4,025,731.190
5,556,689.763
5,477,652.095
EBITDA
3,103,623.585
4,986,260.544
4,900,973.864
6,486,127.242
6,221,480.346
Reconciled Cost of Revenue
66,231,662.944
65,045,061.404
62,472,768.682
61,328,109.615
57,510,951.746
Reconciled Depreciation
870,280.293
894,827.197
875,242.675
929,437.480
743,828.251
Net Income from Continuing Operation Net Minority Interest
2,164,606.831
2,983,113.595
2,835,496.164
4,055,678.691
3,966,522.219
Total Unusual Items Excluding Goodwill
-133,709.812
-131,325.635
-462,618.109
-50,772.322
-60,868.728
Total Unusual Items
-133,709.812
-131,325.635
-462,618.109
-50,772.322
-60,868.728
Normalized EBITDA
3,237,333.397
5,117,586.180
5,363,591.973
6,536,899.564
6,282,349.075
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-22,928.801
-22,393.984
-77,819.239
-8,456.295
-9,533.271
12/31/2022 - 1/4/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: